INBX Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -- compared to Inhibrx Biosciences's net margin of --. Inhibrx Biosciences's return on equity of 2616.46% beat CEL-SCI's return on equity of --.

Inhibrx Biosciences has a consensus price target of --, signalling upside risk potential of 2.25%. On the other hand CEL-SCI has an analysts' consensus of $7.40 which suggests that it could grow by 2351.14%. Given that CEL-SCI has higher upside potential than Inhibrx Biosciences, analysts believe CEL-SCI is more attractive than Inhibrx Biosciences.

Inhibrx Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.414%.

Inhibrx Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inhibrx Biosciences pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Inhibrx Biosciences quarterly revenues are $100K, which are larger than CEL-SCI quarterly revenues of --. Inhibrx Biosciences's net income of -$43.9M is lower than CEL-SCI's net income of -$7.1M. Notably, Inhibrx Biosciences's price-to-earnings ratio is 0.12x while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inhibrx Biosciences is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to Inhibrx Biosciences's net margin of -711.67%. Inhibrx Biosciences's return on equity of 2616.46% beat IGC Pharma's return on equity of -116.24%.

Inhibrx Biosciences has a consensus price target of --, signalling upside risk potential of 2.25%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1030.73%. Given that IGC Pharma has higher upside potential than Inhibrx Biosciences, analysts believe IGC Pharma is more attractive than Inhibrx Biosciences.

Inhibrx Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.213, suggesting its more volatile than the S&P 500 by 21.346%.

Inhibrx Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inhibrx Biosciences pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Inhibrx Biosciences quarterly revenues are $100K, which are smaller than IGC Pharma quarterly revenues of $257K. Inhibrx Biosciences's net income of -$43.9M is lower than IGC Pharma's net income of -$1.8M. Notably, Inhibrx Biosciences's price-to-earnings ratio is 0.12x while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inhibrx Biosciences is -- versus 20.15x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Inhibrx Biosciences's net margin of -49.65%. Inhibrx Biosciences's return on equity of 2616.46% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Inhibrx Biosciences has a consensus price target of --, signalling upside risk potential of 2.25%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 33.86%. Given that NovaBay Pharmaceuticals has higher upside potential than Inhibrx Biosciences, analysts believe NovaBay Pharmaceuticals is more attractive than Inhibrx Biosciences.

Inhibrx Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

Inhibrx Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inhibrx Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Inhibrx Biosciences quarterly revenues are $100K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Inhibrx Biosciences's net income of -$43.9M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Inhibrx Biosciences's price-to-earnings ratio is 0.12x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inhibrx Biosciences is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Inhibrx Biosciences's net margin of 18.02%. Inhibrx Biosciences's return on equity of 2616.46% beat Protalix BioTherapeutics's return on equity of -29.54%.

Inhibrx Biosciences has a consensus price target of --, signalling upside risk potential of 2.25%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 547.32%. Given that Protalix BioTherapeutics has higher upside potential than Inhibrx Biosciences, analysts believe Protalix BioTherapeutics is more attractive than Inhibrx Biosciences.

Inhibrx Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.611%.

Inhibrx Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inhibrx Biosciences pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Inhibrx Biosciences quarterly revenues are $100K, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. Inhibrx Biosciences's net income of -$43.9M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, Inhibrx Biosciences's price-to-earnings ratio is 0.12x while Protalix BioTherapeutics's PE ratio is 121.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inhibrx Biosciences is -- versus 3.85x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.